Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 8, Issue 2, Pages 219-244
Publisher
Informa Healthcare
Online
2012-12-12
DOI
10.1517/17460441.2013.741580
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
- (2013) John B. Buse et al. ANNALS OF INTERNAL MEDICINE
- The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis
- (2012) Niels Vrang et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia
- (2012) Jacob Lønborg et al. Circulation-Cardiovascular Interventions
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
- (2012) Vanita R. Aroda et al. CLINICAL THERAPEUTICS
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
- (2012) M. Wenten et al. DIABETIC MEDICINE
- Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
- (2012) D. Nathanson et al. DIABETOLOGIA
- Exenatide Alters Myocardial Glucose Transport and Uptake Depending on Insulin Resistance and Increases Myocardial Blood Flow in Patients with Type 2 Diabetes
- (2012) M. Gejl et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors
- (2012) S. L. Dickson et al. JOURNAL OF NEUROSCIENCE
- Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis
- (2012) Yazhou Li et al. PLoS One
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual -Cell Function
- (2011) U. Kielgast et al. DIABETES CARE
- Standards of Medical Care in Diabetes--2012
- (2011) DIABETES CARE
- The effects of exenatide bid on metabolic control, medication use and hospitalization in patients with type 2 diabetes mellitus in clinical practice: a systematic review
- (2011) J. H. Best et al. DIABETES OBESITY & METABOLISM
- A cohort study of acute pancreatitis in relation to exenatide use
- (2011) D. D. Dore et al. DIABETES OBESITY & METABOLISM
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- Liraglutide as additional treatment for type 1 diabetes
- (2011) Ajay Varanasi et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
- (2011) Michael Elashoff et al. GASTROENTEROLOGY
- Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
- (2010) Krystyna Tatarkiewicz et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use
- (2010) Sarah L Anderson et al. ANNALS OF PHARMACOTHERAPY
- Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection
- (2010) Alexander Harkavyi et al. BRITISH JOURNAL OF PHARMACOLOGY
- The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
- (2010) Que Liu et al. Cardiovascular Diabetology
- Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
- (2010) Que Liu et al. Cardiovascular Diabetology
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis
- (2010) R. Garg et al. DIABETES CARE
- Exenatide is Non-inferior to Insulin in Reducing HbA1c: An Integrated Analysis of 1423 Patients with Type 2 Diabetes
- (2010) Thomas Blevins et al. POSTGRADUATE MEDICINE
- Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
- (2009) T. Okerson et al. AMERICAN JOURNAL OF HYPERTENSION
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model
- (2009) Kunio Hirata et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus
- (2009) J. S. FREEMAN CLEVELAND CLINIC JOURNAL OF MEDICINE
- Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
- (2009) David D. Dore et al. CURRENT MEDICAL RESEARCH AND OPINION
- Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice
- (2009) J. A. Koehler et al. DIABETES
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
- (2009) J. S. Nachnani et al. DIABETOLOGIA
- The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
- (2009) J. Hsieh et al. DIABETOLOGIA
- Exenatide Reduces Infarct Size and Improves Cardiac Function in a Porcine Model of Ischemia and Reperfusion Injury
- (2009) Leo Timmers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Exenatide Improves Hypertension in a Rat Model of the Metabolic Syndrome
- (2009) Kevin D. Laugero et al. Metabolic Syndrome and Related Disorders
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways
- (2008) Kiwon Ban et al. CIRCULATION
- Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
- (2008) Bronislava R. Gedulin et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- The incretin system and its role in type 2 diabetes mellitus
- (2008) J HOLST et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Fatty Liver
- (2007) Anna Kotronen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now